Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,otherLiab,treasuryStock,otherAssets,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,netReceivables,accountsPayable,otherCurrentAssets,changeToLiabilities,totalCashflowsFromInvestingActivities,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,otherCashflowsFromInvestingActivities,changeToNetincome,capitalExpenditures,otherCashflowsFromFinancingActivities,WC,language,region,quoteType,triggerable,quoteSourceName,currency,esgPopulated,tradeable,exchangeDataDelayedBy,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,epsCurrentYear,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,priceEpsCurrentYear,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,priceHint,exchange,marketState,market,shortName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Jun 14, 2021) 4","Short Ratio (Jun 14, 2021) 4","Short % of Float (Jun 14, 2021) 4","Short % of Shares Outstanding (Jun 14, 2021) 4","Shares Short (prior month May 13, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,state,compensationAsOfEpochDate,country,website,maxAge,address1,industry
t0,ITOS,312609000.0,35099000,11643000,,-13534000,,-13534000,7046000,0,-18689000,-18689000,,,,,,0,0,18689000,0,5155000,,-13534000,-13534000,399694000.0,20280000.0,312609000.0,666000.0,332889000.0,35000.0,-87432000.0,5947000.0,312000.0,3574000.0,321385000.0,11830000.0,312000.0,4396000.0,324919000.0,1241000.0,5300000.0,,-1392000.0,-91000.0,667000.0,-2580000.0,667000.0,-14931000.0,-717000.0,-14790000.0,126000.0,-3000.0,2590000.0,-88000.0,,313089000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,False,False,0,11.15,0.6397016,17.43 - 47.61,-19.03,-0.39970595,17.43,47.61,1616616000,1616616000,1616616000,2.11,0.8112859,27.9101 - 28.6499,28.35,0.0,0.0,10,8,finmb_663087242,NasdaqGM,"iTeos Therapeutics, Inc.",USD,457418,121914,13.545024,25.302856,3.2771435,0.12951674,27.504059,1.0759411,0.039119355,1003129408,15,America/New_York,EDT,-14400000,2,NGM,PRE,us_market,"iTeos Therapeutics, Inc.",28.58,1630526403,0.22999954,28.25,28.6499,27.9101,115806,,,,47.61,17.43,25.3,27.5,457.42k,121.91k,35.1M,,17.35M,0.71%,87.33%,1.68M,2.7,8.39%,4.79%,1.93M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-14.27%,-20.49%,,,,,-55.04M,-50.39M,,,321.38M,9.16,3.05M,0.98,27.47,,-40.49M,-28.61M,Value,02142,Healthcare,68,"Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2a receptor that is an open-label Phase 1/2a clinical trial in adult patients; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2a clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts.",Cambridge,339 217 0161,MA,1609372800,United States,http://www.iteostherapeutics.com,86400,139 Main Street,Biotechnology
t-1,ITOS,323197000.0,35099000,9569000,,-14903000,,-14904000,5729000,0,-15298000,-15298000,,,,,,1000,0,15298000,0,395000,,-14904000,-14904000,396443000.0,21361000.0,323197000.0,4486000.0,344558000.0,35000.0,-73898000.0,6363000.0,617000.0,3662000.0,336326000.0,14998000.0,617000.0,1352000.0,339544000.0,325000.0,3026000.0,,3149000.0,-134000.0,833000.0,4130000.0,667000.0,-3653000.0,1112000.0,-5464000.0,143000.0,-3000.0,2018000.0,-134000.0,833000.0,324546000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,False,False,0,11.15,0.6397016,17.43 - 47.61,-19.03,-0.39970595,17.43,47.61,1616616000,1616616000,1616616000,2.11,0.8112859,27.9101 - 28.6499,28.35,0.0,0.0,10,8,finmb_663087242,NasdaqGM,"iTeos Therapeutics, Inc.",USD,457418,121914,13.545024,25.302856,3.2771435,0.12951674,27.504059,1.0759411,0.039119355,1003129408,15,America/New_York,EDT,-14400000,2,NGM,PRE,us_market,"iTeos Therapeutics, Inc.",28.58,1630526403,0.22999954,28.25,28.6499,27.9101,115806,,,,47.61,17.43,25.3,27.5,457.42k,121.91k,35.1M,,17.35M,0.71%,87.33%,1.68M,2.7,8.39%,4.79%,1.93M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-14.27%,-20.49%,,,,,-55.04M,-50.39M,,,321.38M,9.16,3.05M,0.98,27.47,,-40.49M,-28.61M,Value,02142,Healthcare,68,"Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2a receptor that is an open-label Phase 1/2a clinical trial in adult patients; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2a clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts.",Cambridge,339 217 0161,MA,1609372800,United States,http://www.iteostherapeutics.com,86400,139 Main Street,Biotechnology
t-2,ITOS,335626000.0,35099000,8453000,,-10688000,,-10680000,4799000,0,-13252000,-13252000,,,,,,-8000,0,13252000,0,2564000,,-10680000,-11647000,394488000.0,15318000.0,335626000.0,1862000.0,350944000.0,35000.0,-58994000.0,4993000.0,97000.0,3923000.0,339981000.0,10325000.0,97000.0,1287000.0,345734000.0,2491000.0,2409000.0,,351000.0,-105000.0,212873000.0,-1761000.0,214110000.0,203114000.0,577000.0,-10231000.0,142000.0,-2000.0,1717000.0,-103000.0,-1237000.0,335409000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,False,False,0,11.15,0.6397016,17.43 - 47.61,-19.03,-0.39970595,17.43,47.61,1616616000,1616616000,1616616000,2.11,0.8112859,27.9101 - 28.6499,28.35,0.0,0.0,10,8,finmb_663087242,NasdaqGM,"iTeos Therapeutics, Inc.",USD,457418,121914,13.545024,25.302856,3.2771435,0.12951674,27.504059,1.0759411,0.039119355,1003129408,15,America/New_York,EDT,-14400000,2,NGM,PRE,us_market,"iTeos Therapeutics, Inc.",28.58,1630526403,0.22999954,28.25,28.6499,27.9101,115806,,,,47.61,17.43,25.3,27.5,457.42k,121.91k,35.1M,,17.35M,0.71%,87.33%,1.68M,2.7,8.39%,4.79%,1.93M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-14.27%,-20.49%,,,,,-55.04M,-50.39M,,,321.38M,9.16,3.05M,0.98,27.47,,-40.49M,-28.61M,Value,02142,Healthcare,68,"Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2a receptor that is an open-label Phase 1/2a clinical trial in adult patients; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2a clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts.",Cambridge,339 217 0161,MA,1609372800,United States,http://www.iteostherapeutics.com,86400,139 Main Street,Biotechnology
t-3,ITOS,-47922000.0,35099000,5951000,,-7252000,,-7202000,2394000,0,-8345000,-8345000,,,,,,-50000,0,8345000,0,1093000,,-7202000,-10302000,687000.0,12161000.0,-47922000.0,1500000.0,145211000.0,1000.0,-48314000.0,4645000.0,-296000.0,3565000.0,136870000.0,7516000.0,-296000.0,1251000.0,140395000.0,345000.0,2656000.0,1700000.0,-3116000.0,-101000.0,-1106000.0,-161000.0,205000.0,-10860000.0,349000.0,-10002000.0,129000.0,-9000.0,348000.0,-92000.0,-1311000.0,132879000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,False,False,0,11.15,0.6397016,17.43 - 47.61,-19.03,-0.39970595,17.43,47.61,1616616000,1616616000,1616616000,2.11,0.8112859,27.9101 - 28.6499,28.35,0.0,0.0,10,8,finmb_663087242,NasdaqGM,"iTeos Therapeutics, Inc.",USD,457418,121914,13.545024,25.302856,3.2771435,0.12951674,27.504059,1.0759411,0.039119355,1003129408,15,America/New_York,EDT,-14400000,2,NGM,PRE,us_market,"iTeos Therapeutics, Inc.",28.58,1630526403,0.22999954,28.25,28.6499,27.9101,115806,,,,47.61,17.43,25.3,27.5,457.42k,121.91k,35.1M,,17.35M,0.71%,87.33%,1.68M,2.7,8.39%,4.79%,1.93M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-14.27%,-20.49%,,,,,-55.04M,-50.39M,,,321.38M,9.16,3.05M,0.98,27.47,,-40.49M,-28.61M,Value,02142,Healthcare,68,"Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2a receptor that is an open-label Phase 1/2a clinical trial in adult patients; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2a clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts.",Cambridge,339 217 0161,MA,1609372800,United States,http://www.iteostherapeutics.com,86400,139 Main Street,Biotechnology
